Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $25.11 USD
Change Today -0.12 / -0.48%
Volume 14.3K
FLDM On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 10:38 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

fluidigm corp (FLDM) Snapshot

Open
$25.05
Previous Close
$25.23
Day High
$25.24
Day Low
$24.86
52 Week High
03/20/15 - $46.38
52 Week Low
10/13/14 - $21.71
Market Cap
722.8M
Average Volume 10 Days
823.6K
EPS TTM
$-1.99
Shares Outstanding
28.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FLUIDIGM CORP (FLDM)

Related News

No related news articles were found.

fluidigm corp (FLDM) Related Businessweek News

No Related Businessweek News Found

fluidigm corp (FLDM) Details

Fluidigm Corporation creates, manufactures, and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics. It provides various preparatory instruments, including C1 single-cell auto prep system, a sample preparation system that isolates, processes, and profiles individual cells for genomic analysis; and access array systems that enables automated polymerase chain reaction (PCR)-based target enrichment, barcoding, and tagging of resequencing libraries and facilitates parallel amplification. The company also offers analytical instruments comprising Biomark HD system, a PCR analytical instrument for gene expression analysis, single-cell targeted gene expression analysis, microRNA analysis, single nucleotide polymorphism (SNP) genotyping, and digital PCR; EP1 system that performs high-throughput SNP genotyping and end-point digital PCR; and CyTOF 2 system, a mass cytometry instrument that performs single-cell protein analysis by analyzing cells labeled with a panel of reagents conjugated to stable metal isotopes. In addition, it provides integrated fluidic circuits (IFCs), such as C1, access array, dynamic array, digital array, and flex six IFCs; assays and reagents consisting of Delta Gene and SNP type assays, access array target-specific primers, and Maxpar Reagents. Further, the company’s products include juno systems and IFCs, callisto systems and IFCs, polaris systems and IFCs, and C1 mRNA Sequencing IFCs. It serves academic institutions; clinical laboratories; and pharmaceutical, biotechnology, and agricultural biotechnology companies. The company distributes its products through direct sales force and support organizations, distributors, or sales agents. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

474 Employees
Last Reported Date: 02/26/15
Founded in 1999

fluidigm corp (FLDM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $490.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $320.0K
Chief Operating Officer
Total Annual Compensation: $325.0K
Executive Vice President of Legal Affairs, Ge...
Total Annual Compensation: $325.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

fluidigm corp (FLDM) Key Developments

Fluidigm Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revised Earnings Guidance for the Full Year of 2015

Fluidigm Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net loss of $15,931,000 or $0.56 per basic and diluted share on total revenue of $26,729,000 against net loss of $15,414,000 or $0.57 per basic and diluted share on total revenue of $25,724,000 a year ago. Loss from operations of $14,001,000 compared to $16,579,000 a year ago. Loss before income taxes of $16,574,000 compared to $17,557,000 a year ago. Net cash used in operating activities of $9,800,000 compared to $10,547,000 a year ago. Purchases of property and equipment of $909,000 compared to $1,813,000 a year ago. Non-GAAP net loss was $7,258,000 or $0.25 per basic and diluted share against net income of $75,000 a year ago. For the full year of 2015, the company is projecting total revenue to be between $133 million and $143 million versus prior guidance of between $142 million and $149 million. 2015 revenue projections incorporate an estimated negative currency related impact of approximately 4% to 5% at the midpoint of the range versus the company prior estimate of approximately 3% to 4%. The company projects 2015 operating expenses on a GAAP basis to be between $129 and $134 million. Non-GAAP operating expenses, excluding approximately $19 million of estimated stock-based compensation expense, and $5 million of estimated depreciation and amortization expense, is expected to be between $105 million and $110 million.

Fluidigm Corporation Appoints Steve McPhail as General Manager of Production Genomics Business

Fluidigm Corporation recruited Steven C. McPhail to lead its new organization specifically focused on serving its production genomics customers. Prior to joining Fluidigm, McPhail dedicated 12+ years to Expression Analysis, which was acquired by Quintiles Transnational Corporation in 2012, where he served as President of the post-acquisition operation. Prior to Expression Analysis, McPhail spent his career serving companies in the diagnostic, biotechnology and medical device markets, including ArgoMed, Xanthon, TriPath Imaging, Dynex Technologies and Abbott Laboratories.

Fluidigm Corporation to Report Q1, 2015 Results on May 07, 2015

Fluidigm Corporation announced that they will report Q1, 2015 results at 2:00 PM, Pacific Daylight on May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLDM:US $25.11 USD -0.12

FLDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biotage AB kr18.50 SEK +0.30
Luminex Corp $16.63 USD 0.00
NanoString Technologies Inc $14.19 USD +0.13
Pacific Biosciences of California Inc $5.85 USD +0.03
Trovagene Inc $10.66 USD +0.3694
View Industry Companies
 

Industry Analysis

FLDM

Industry Average

Valuation FLDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.3x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLUIDIGM CORP, please visit www.fluidigm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.